Document is current
Any future updates will be listed below
-
Authors
Karmakar, Subir
Volpedo, Greta
Zhang, Wen-Wei https://orcid.org/0000-0003-1996-876X
Lypaczewski, Patrick https://orcid.org/0000-0002-5550-712X
Ismail, Nevien https://orcid.org/0000-0003-0294-8834
Oliveira, Fabiano https://orcid.org/0000-0002-7924-8038
Oristian, James
Meneses, Claudio
Gannavaram, Sreenivas https://orcid.org/0000-0002-6557-8220
Kamhawi, Shaden https://orcid.org/0000-0003-4304-636X
Hamano, Shinjiro https://orcid.org/0000-0003-3881-8337
Valenzuela, Jesus G. https://orcid.org/0000-0002-5589-9450
Matlashewski, Greg https://orcid.org/0000-0002-8971-5525
Satoskar, Abhay R. https://orcid.org/0000-0001-5989-1520
Dey, Ranadhir https://orcid.org/0000-0003-0069-7867
Nakhasi, Hira L. https://orcid.org/0000-0003-4941-1620
-
Funding
Funding for this research was provided by:
Global Health Innovative Technology Fund
- License Information
-
More Information
Article History
Received: 1 June 2022
Accepted: 7 November 2022
First Online: 3 December 2022
Competing interests
: The FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania</i> species with the <i>centrin</i> gene deletion (US7,887,812 and US 8,877,213). All other authors declare no competing interests.
